CSF2 receptor mediated actions in t(8;21) leukemia

CSF2 受体介导的 t(8;21) 白血病作用

基本信息

  • 批准号:
    9014529
  • 负责人:
  • 金额:
    $ 34.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-02-13 至 2020-01-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The overall goal of this proposal is to understand the role of CSF2 and its specific receptor CSF2Rα in the development of t(8;21) leukemia. The 8 and 21 chromosome translocation, t(8;21)(q22;q22), is responsible for the development of 40% of FAB M2 type of acute myeloid leukemia (AML) and is reported in 8-15% of cases of AML, depending on geographic locations and ethnic groups. Age is the most correlated factor for AML. Most AML patients are over 60 years old at the initial diagnosis. However, t(8;21) AML patients are relatively young and most respond to initial chemotherapy well. Therefore, t(8;21) AML is generally considered with favorable prognosis. However, the cumulative incidence of relapse in 5 years is 47%, and the median overall survival time is only 5 years among de novo t(8;21) AML patients. Furthermore, therapy-related t(8;21) AML does not have a favorable outcome. Therefore, it is important to identify new approaches to eliminate t(8;21) leukemia stem cells during the initial induction treatment and to block the survival and proliferation of chemo-resistant leukemia cells. The fusion of ETO gene on chromosome 8 and AML1 gene on chromosome 21 in t(8;21) leads to the expression of the abnormal AML1-ETO protein. Using several transgenic mouse models and available human patient data, we discovered that colony stimulating factor 2 (CSF2) negatively regulates AML1-ETO induced self-renewal of hematopoietic stem/progenitor cells and AML development. Furthermore, expression of the CSF2-specific receptor subunit, CSF2Rα, in t(8;21) AML cells reduces cell proliferation and survival. In this funding application, we will test the hypotheses that selected CSF2 downstream pathways play critical roles in suppression of t(8;21) leukemia and that CSF2Rα may have functions independent of CSF2 signaling in inhibition of t(8;21) leukemia. We propose to perform the following studies to test the hypotheses: in specific aim 1, we will characterize the molecular pathways of CSF2 signaling that mediate inhibition of AML1-ETO induced leukemia; in specific aim 2, we will analyze the effect of CSF2RA expression on t(8;21) leukemogenesis. The proposed studies are based on our accumulated knowledge and recent novel findings involving CSF2 signaling and CSF2Rα in AML1-ETO induced leukemia. Collectively, our proposal will address important unanswered questions in hematopoiesis and leukemogenesis, which aim to provide valuable insight into the treatment of t(8;21) leukemia.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DONG-ER ZHANG其他文献

DONG-ER ZHANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DONG-ER ZHANG', 18)}}的其他基金

USP18 in Cancer Development
USP18 在癌症发展中的作用
  • 批准号:
    10596566
  • 财政年份:
    2019
  • 资助金额:
    $ 34.49万
  • 项目类别:
USP18 in Cancer Development
USP18 在癌症发展中的作用
  • 批准号:
    9886213
  • 财政年份:
    2019
  • 资助金额:
    $ 34.49万
  • 项目类别:
USP18 in Cancer Development
USP18 在癌症发展中的作用
  • 批准号:
    10377534
  • 财政年份:
    2019
  • 资助金额:
    $ 34.49万
  • 项目类别:
USP18 in Cancer Development
USP18 在癌症发展中的作用
  • 批准号:
    10132268
  • 财政年份:
    2019
  • 资助金额:
    $ 34.49万
  • 项目类别:
CSF2 receptor mediated actions in t(8;21) leukemia
CSF2 受体介导的 t(8;21) 白血病作用
  • 批准号:
    8842430
  • 财政年份:
    2015
  • 资助金额:
    $ 34.49万
  • 项目类别:
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology
SRF2 和 RUNX1 在血细胞发育和病理学中的协同作用
  • 批准号:
    10400021
  • 财政年份:
    2013
  • 资助金额:
    $ 34.49万
  • 项目类别:
ISG15 and protein ISGylation in Cancer
癌症中的 ISG15 和蛋白质 ISGylation
  • 批准号:
    8616739
  • 财政年份:
    2013
  • 资助金额:
    $ 34.49万
  • 项目类别:
ISG15 and protein ISGylation in Cancer
癌症中的 ISG15 和蛋白质 ISGylation
  • 批准号:
    8535417
  • 财政年份:
    2013
  • 资助金额:
    $ 34.49万
  • 项目类别:
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology
SRF2 和 RUNX1 在血细胞发育和病理学中的协同作用
  • 批准号:
    9922899
  • 财政年份:
    2013
  • 资助金额:
    $ 34.49万
  • 项目类别:
ISG15 and Protein ISGylation in Cancer
癌症中的 ISG15 和蛋白质 ISG 化
  • 批准号:
    10116297
  • 财政年份:
    2013
  • 资助金额:
    $ 34.49万
  • 项目类别:

相似海外基金

Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
  • 批准号:
    19K08356
  • 财政年份:
    2019
  • 资助金额:
    $ 34.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
  • 批准号:
    23501309
  • 财政年份:
    2011
  • 资助金额:
    $ 34.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
  • 批准号:
    3556971
  • 财政年份:
    1980
  • 资助金额:
    $ 34.49万
  • 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
  • 批准号:
    3556968
  • 财政年份:
    1980
  • 资助金额:
    $ 34.49万
  • 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
  • 批准号:
    3889304
  • 财政年份:
  • 资助金额:
    $ 34.49万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了